Lumonus, a provider of AI-driven radiation oncology workflow solutions, announced the completion of an A$25 million financing round led by Aviron Investment Management, with continued support from Oncology Ventures.
The investment underscores growing global adoption of Lumonus AI across health systems in the United States, Australia, and Europe. The platform has assisted clinicians in over 280,000 cancer treatment consultations and prescriptions, automating more than 75,000 treatment plans. This achievement highlights the platform’s role in optimizing oncology workflows and enhancing efficiency in cancer care delivery.
The leadership team combines over a century of clinical, operational, and technical expertise from major cancer centers across multiple regions, ensuring deep alignment with the realities of oncology care and driving continued innovation in treatment workflow solutions.
“Oncology is at an inflection point,” said Keith Hansen, Chief Executive Officer of Lumonus. “Scientific innovation in cancer treatment has advanced significantly, but the systems that support teams delivering the care have not kept pace. By combining AI-native architecture, a comprehensive end-to-end workflow approach, and a commitment to partnering with care teams to solve real-world pain points, we are reimagining oncology workflows. This investment allows us to expand our world-class team and support more health systems that are ready to embrace a better way.”
“This milestone reflects the dedication of our entire team, who have worked side by side with clinicians worldwide to demonstrate real impact in oncology today and to show what the future of cancer care can be,” said Merrick Howes, Chairman of Lumonus. “Our unique AI-native platform has already demonstrated its ability to improve clinical quality and operational efficiency. This new capital will allow us to accelerate both product innovation and expand our U.S. commercial footprint.”
Ben Freeberg, Managing Partner at Oncology Ventures, added, “The Lumonus team combines deep clinical expertise with world-class product execution and has already earned the trust of leading cancer centers internationally. We are proud to support Lumonus as they continue to deliver measurable impact and set the standard for the future of oncology workflows.”
The new funding will drive expansion of U.S. market operations, advancement of flagship products — Lumonus AI Physician and Lumonus AI Dosimetry — and enhancement of clinical informatics capabilities. Additional initiatives include deeper collaboration with health systems to leverage real-world evidence, elevate care quality, improve performance, and enable more personalized, data-driven oncology treatment.